Steering Committee 
April W. Armstrong, MD, MPH
Associate Dean, Clinical Research
Professor of Dermatology
Director, Clinical Research Support, Southern California CTSI
Keck School of Medicine
University of Southern California
Los Angeles, CA

Andrew Blauvelt, MD, MBA
President
Oregon Medical Research Center
Portland, OR

M. Elaine Husni, MD, MPH
Vice Chair, Department of Rheumatic and Immunologic Diseases
Director of the Arthritis & Musculoskeletal Center
Scholtz Family Endowed Chair
Cleveland Clinic
Cleveland, OH

Target Audience 
This CME-certified activity has been designed to meet the educational needs of dermatologists, rheumatologists, nurse practitioners, and PAs. It may also be of benefit to other physicians, nurses, and other healthcare practitioners who are involved in the management of psoriasis.

This activity is provided by the University of Cincinnati.      

Paradigm Medical Communications, LLC is the educational partner.  

Supporter Acknowledgment 
This activity is supported by an educational grant from Bristol Myers Squibb Company.

Program Overview 
Psoriasis is an immune-mediated disease characterized by hyperproliferation of keratinocytes resulting in a red, itchy, scaling rash that negatively impacts quality of life for patients. In addition, systemic inflammation may manifest in psoriatic disease in the joints and spine, associated inflammatory bowel disease or uveitis, and metabolic or cardiovascular disease. Systemic treatments are available for moderate-to-severe psoriasis that target specific proinflammatory cytokines. These are associated with high levels of skin disease clearance and reduction of arthritis symptoms for patients. However, not all patients respond to, or can tolerate, current biologic agents; or disease progression can occur despite optimal therapy, fueling a need for additional novel therapies. Janus kinase (JAK) inhibitors target intracellular signaling pathways of multiple cytokines active in psoriatic disease. JAK inhibitors have demonstrated efficacy in psoriatic disease but have safety concerns associated with effects on hematopoiesis and reports that show increased risk of thrombotic and cardiovascular events and malignancy. Emerging tyrosine kinase 2 (TYK2) inhibitors offer greater specificity, and a potentially greater safety profile stemming from increased specificity and selectivity. Clinicians need to differentiate between JAK-mediated cytokines and TYK2-mediated cytokines, mechanisms of action (MOA), and potential safety effects of TYK2 versus JAK inhibitors. As data emerge, clinicians will need to consider outcomes with respect to mechanisms to inform future clinical application.
  
Learning Objectives
Upon completion of this activity, participants should be able to:

• Compare cytokines mediated by JAKs with those mediated by TYK2 and their roles in the pathophysiology of psoriasis
• Distinguish between the MOA of JAK and TYK2 inhibitors and implications for the treatment of psoriasis
• Outline the potential roles of JAK and TYK2 inhibitors in the treatment of psoriasis

Agenda 

• Cytokines in the Pathophysiology of Psoriasis
• Rationale for JAK/TYK2 Inhibition in Psoriasis
• Q&A

Physician Accreditation Statement
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

ABIM MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

How to Receive Your CE Credit 
To receive a CE certificate of participation, you must:

• Complete the pre-assessment survey prior to the live activity
• Attend the live activity
• Complete and return the activity post-assessment survey, evaluation, and request for credit forms to a Paradigm staff member as you exit

• Complete the pre-assessment survey prior to the live activity
• Attend the live virtual activity in its entirety
• At the conclusion of the activity, complete the activity post-assessment survey, evaluation, and request for credit at: www.surveymonkey.com/r/3JX2P38

A certificate of participation will be issued 1 to 2 weeks following the meeting.
For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.

There are no fees for participating in this activity.

Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, University of Cincinnati requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to University of Cincinnati policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. University of Cincinnati is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated. 

Steering Committee
April W. Armstrong, MD, MPH
Consultant: AbbVie Inc; Almirall, S.A.; Arcutis Biotherapeutics; ASLAN Pharmaceuticals; Beiersdorf Global; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Dermavant Sciences, Inc.; Dermira; Eli Lilly and Company; EPI Health, LLC; Incyte; Janssen Pharmaceuticals, Inc; LEO Pharma Inc; Modernizing Medicine; Nimbus Therapeutics; Novartis AG; Ortho Dermatologics; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sanofi; Sun Pharmaceuticals Industries Ltd; UCB S.A.

Andrew Blauvelt, MD, MBA
Advisor: AbbVie Inc; Abcentra; Affibody Medical AB; Aligos Therapeutics; Almirall, S.A.; Alumis Inc.; Amgen Inc; AnaptysBio, Inc; Arcutis Biotherapeutics; Arena Pharmaceuticals, Inc.; ASLAN Pharmaceuticals; Athenex, Inc.; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Cara Therapeutics; Dermavant Sciences, Inc.; EcoR1 Capital, LLC; Eli Lilly and Company; Evelo Biosciences, Inc.; Evomune, Inc.; Forte Biosciences, Inc.; Galderma Laboratories, L.P.; Highlightll Pharma, InCyte; Janssen Pharmaceuticals, Inc; Landos Biopharma; LEO Pharma Inc; Merck & Co, Inc; Novartis AG; Pfizer Inc; RAPT Therapeutics; Regeneron Pharmaceuticals, Inc; Sanofi Genzyme; Spherix Global Insights; Sun Pharmaceutical Industries Ltd; TLL Pharmaceutical; TrialSpark; UCB S.A.; Vibliome Therapeutics, LLC; Xencor
Speakers’ Bureau: AbbVie Inc; Eli Lilly and Company; UCB S.A.
Clinical Study Investigator/Institution: AbbVie Inc; Acelyrin, Inc.; Amgen Inc; Arcutis Biotherapeutics; Athenex, Inc.; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Dermavant Sciences, Inc.; Eli Lilly and Company; Evelo Biosciences, Inc.; Galderma Laboratories, L.P.; InCyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc; Merck & Co, Inc; Novartis AG; Pfizer Inc; Regeneron Pharmaceuticals, Inc; Sun Pharmaceutical Industries Ltd; UCB S.A.

M. Elaine Husni, MD, MPH
Consultant: AbbVie Inc; Bristol Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc; Novartis AG; UCB S.A.

Barb Forney has no relevant financial relationships with ineligible companies to disclose.

Bruce Gebhardt, MD has no relevant financial relationships with ineligible companies to disclose.

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

© 2022 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.